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Abstract
A 68-year-old woman presented with acute chest pain and a greatly increased platelet count.
Cardiac catheterization revealed subtotal occlusion and a thrombus-like filling defect in the right
coronary artery. The patient was successfully treated with intravenous tirofiban. Essential
thrombocythemia was diagnosed based on bone marrow findings, clinical presentation and
laboratory analysis. The relationship between intracoronary thrombus and essential
thrombocythemia is discussed.
Introduction
Essential thrombocythemia (ET) is a clonal disorder of
unknown etiology involving a multipotent hematopoietic
progenitor cell and is manifested clinically by the overpro-
duction of platelets in the absence of a definable cause [1].
In 2008, the World Health Organization accepted the
presence of the JAK2V617F mutation as a new diagnostic
criterion for myeloproliferative neoplasms (MPNs) like
polycythemia vera (PV), essential thrombocythemia (ET)
and primary myelofibrosis (PMF) [2]. Platelets in this dis-
order also tend to be dysfunctional, in addition to being
elevated in number [3]. The disease is associated with an
elevated risk of thrombosis, hemorrhage, and vasomotor
symptoms. Thrombotic events are not common but are
usually deep venous thrombosis and pulmonary emboli
[4,5]. Coronary artery involvement is uncommon. We
present a case of coronary thrombus involving the right
coronary artery in a patient with ET.
Case presentation
A 68-year-old woman was admitted to our institution
because of severe and sudden-onset chest pain. She under-
went coronary angiography a year before which revealed a
normal right coronary artery (RCA) with nonsignificant
atherosclerotic lesions involving the other remaining cor-
onary arteries. Her past medical history was significant for
high platelet counts with a nonrevealing workup for mye-
loproliferative disease, and diabetes which was controlled
medically. The patient's blood pressure on presentation
was 135/70 mmHg with a heart rate of 70 beats/minute.
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Physical examination revealed splenomegaly without any
other significant pathological findings. Electrocardiogra-
phy showed regular sinus rhythm with ST segment depres-
sion in the inferior derivations. The patient was diagnosed
as having acute coronary syndrome (ACS). She was trans-
ported immediately to the catheterization laboratory.
Coronary angiography, performed via the right femoral
artery, showed subtotal occlusion and thrombus-like fill-
ing defect in the mid portion of the RCA (Figure 1). The
left circumflex (LCx) and the left anterior descending
artery (LAD) exhibited only mild irregularities without
significant stenosis (Figure 2). Percutaneous coronary
intervention was not performed. The patient was trans-
ferred to the coronary care unit where continuous infu-
sion of tirofiban (0.4 mcg/kg/min bolus) over 30 minutes
followed by 0.25 mcg/kg/min for 24 hours, heparin
(1000 U/hours), and the oral combination of clopidogrel
(75 mg/d before 300 mg bolus), plus aspirin (100 mg/
day) was re-instituted. We kept the activated clotting time
between 250 and 300 s during the infusion of heparin and
tirofiban. A control coronary angiogram obtained three
days later showed total dissolution of the coronary throm-
bus and normal clearance of the culprit vessel and TIMI-
III flow was seen (Figure 3). Also, there was no distal
embolization. Laboratory analysis showed leukocytosis
(WBC: 17300/mm3) and thrombocytosis (platelet
count:1.243.000/mm3). Bone marrow aspirate revealed
myeloid and megakaryocytic hyperplasia with mild
degree fibrosis (Figure 4). Bone marrow biopsy of the
patient was consistent with typical myeloproliferative dis-
ease and aspiration samples were sent to the Molecular
Biology Laboratories of the Medical Biology Department,
Ege University. Genomic DNA was extracted from periph-
eral blood leukocytes by using the High Pure PCR Tem-
plate Preparation Kit (Roche Applied Science, Mannheim,
Germany) and stored at -20°C until use. Gene polymor-
phism and mutation analysis was either carried out by
commercial available kits (LightCycler Factor V Leiden
Mutation Detection Kit, and LightCycler Prothrombin
(G20210A) Mutation Detection Kit, Roche Applied Sci-
ence, Mannheim, Germany; LightMix Kit JAK2V617F
Coronary angiography revealing thrombus-like filling defect  in the mid portion of RCA Figure 1
Coronary angiography revealing thrombus-like filling 
defect in the mid portion of RCA.
Left coronary angiography revealed no significant stenosis Figure 2
Left coronary angiography revealed no significant 
stenosis.
Coronary angiography revealing RCA free of thrombus Figure 3
Coronary angiography revealing RCA free of throm-
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genomic, LightMix for the detection of human MTHFR
C677T, and LightMix for the detection of human Plas-
minogen Activator Inhibitor 4G/5G, TIB MOLBIOL, ber-
lin, Germany) or in the case of the Factor XII C46T gene
polymorphism by a protocol published from Tirodo, I. et
al. [6]. All experiments were carried out on the LightCy-
cler™ Instrument ver.2.0 (Roche Applied Science; Man-
nheim, Germany).
Total RNA was isolated from bone marrow cells of the
subject by using the High Pure RNA Isolation Kit (Roche
Applied Science, Mannheim, Germany) and stored at -
86°C until use. Quantitative bcr-abl analysis was per-
formed with the LightCycler t(9;22) Quantification Kit on
the LightCycler™ Instrument ver.2.0 (Roche Applied Sci-
ence; Mannheim, Germany).
Bone marrow specimens were negative for the presence of
the bcr/abl transcript. JAK2V617F mutation, Factor V Lei-
den (G 1691 A), Prothrombin gene (G 20210 A) muta-
tions, MTHFR (C 677 T), Factor XIII (C 46 T), and PAI-1
(4G/5G) genotype polymorphism analysis were per-
formed to determine the potential hereditary risk factors
for thrombophilia. PAI-1 4G/4G homozygote polymor-
phism and JAK2V617F heterozygote mutation were
detected. Bone marrow findings, clinical presentation and
laboratory analysis confirmed the diagnosis of essential
thrombocythemia. Hydroxyurea was given to control the
leukocyte and thrombocyte count.
Discussion
Intracoronary thrombus (ICT) may occur in ACS sponta-
neously, sometimes as a complication of interventional
procedures and frequently superimposes on an existing
atherosclerotic lesion [7]. However, an ICT or myocardial
infarction with normal coronary arteries is a syndrome
resulting from numerous conditions, but the exact cause
in a majority of patients remains unknown. Possible
mechanisms include embolism, vasospasm, nonathero-
sclerotic coronary diseases, hypercoagulable states,
trauma, an imbalance between oxygen demand and sup-
ply, intense sympathetic stimulation, and endothelial dys-
function [8]. Because of RCA was determined as normal
on recent angiogramme, the possible mechanism of
thrombus in our case is considered due to hypercoagulab-
lity that induced essential thrombocythemia.
Myeloproliferative disorders are a heterogeneous group of
diseases characterized by excessive proliferation of cells
originated from the myeloid lineage. Chronic myeloid
leukemia, polycythemia vera, essential thrombocythemia
and myelofibrosis are leading forms of the disorder. ET is
a clonal disorder of a multipotent stem cell resulting in
thrombocytosis, leukocytosis [9,10]. Patients with ET are
thought to be at increased risk of thromboembolic events.
Arterial ischemic complications may occur in these
patients [10]. Elevated platelet count is regarded as risk
factor, although the significance of these parameters has
not been confirmed by clinical studies [11,12].
At diagnosis, 5% of ET patients show chromosomal
abnormalities [13]. The most common cytogenetic abnor-
malities detected by conventional cytogenetic techniques
are deletions in the long arms of chromosomes 20 and 13,
duplication of 1q, and trisomies of chromosomes 8 and 9
[13]. Kralovics et al. [13] found loss of heterozygosity to
be present in chromosome 9p, where JAK2 resides. JAK2
is a member of the Janus family of cytoplasmic non-recep-
tor tyrosine kinases. A guanine-to-thymidine substitution,
which results in a substitution of valine for phenylalanine
at codon 617 of JAK2 (JAK2V617F), is responsible for the
constitutively activity of this tyrosine kinase that activates
signal transducer and activator of transcription (STAT),
mitogen activated protein kinase (MAPK) and phosphoti-
dylinositol 3-kinase (PI3K) signalling pathways, and
transforms haematopoietic progenitor cells [14-16]. The
discovery of JAK2V617F has led to the development of
selective JAK2 inhibitors for the treatment of PV, ET and
PMF (6, 16). Its exon 14 harbors JAK2V617F mutation,
recently reported to be present in approximately 50% of
ET. In addition, JAK2 exon 12 mutation in PV2, and a
thrombopoietin receptor MPLW515L/K mutation in ET
and myelofibrosis [17] are novel mutations that have
been described in JAK2V617F mutation negative patients.
In ET in particular, approximately 50% of the patients are
Bone marrow aspirate showed myeloid and megakaryocytic  and megakaryocytic hyperplasia (A&B) (Hematoxy- lin&Eosin40) with mild degree fibrosisi (Reiculin stain×20) Figure 4
Bone marrow aspirate showed myeloid and meg-
akaryocytic and megakaryocytic hyperplasia (A&B) 
(Hematoxylin&Eosin40) with mild degree fibrosisi 
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JAK2 mutation negative and only a small fraction (less
than 5%) has MPL mutation. However, recent studies
have showed that no significant differences for clinical
complications except megakaryocyte counts between the
patients with JAK2 V617F-positive and -negative [18].
Sarecka et al. reported the relationship between 5G allele
of PAI-1 gene and the coronary artery disease. This data
and the previously recorded data and Hindorff et al.
reported that 4G allele was associated with a reduced risk
of myocardial infarction and in the premenopausal
women group 5G allele was correlated with a higher risk
of infarct [19-21]. Böttiger et al. found no association
between the 4G/5G promoter polymorphism of the PAI-1
gene and angiographic restenosis or clinical outcome after
coronary artery stenting in a large consecutive cohort of
patients [22]. Our case had homozigous PAI-1 4G/4G and
heterozygote JAK2V617F polymorphisms.
Douste-Blazy and associates reported that in cases of ET,
pathophysiologic mechanisms of thrombus formation in
different coronary arteries were 1) activation of thrombo-
cytes as a result of endothelial damage, 2) extended arte-
rial spasms and as a result formation of thrombus, 3)
increased procoagulant activity of thrombocytes, 4)
changes in glycoproteins on the surface of thrombocytes,
and 5) possible deficiency of selective lipooxygenase [23].
ACS, developing in cases of ET, was not a result of athero-
sclerotic plaque rupture and was characterized by forma-
tion of the primary thrombus due to increased numbers of
platelets, frequently in intramural arteries and rarely in
epicardial arteries [24]. In these patients, coronary angi-
ograms are frequently found to be normal [25]. No spe-
cific treatment of ACS, in patients with ET is reported. In
the literature, only rare cases of application of conven-
tional treatment or coronary angioplasty are found [26].
In this case, tirofiban, a GP IIb/IIIa receptor blocker, was
preferably used, taking into account the pathophysiology
of the disease.
Therefore, it may be thought that, in patients with ET,
thrombolytic resistance treatment could develop in ACS
generated by primary platelet rich thrombus, and block-
ing the GP IIb/IIIa receptors could break the continuing
chain of aggregation and activation. Clinical improve-
ment following tirofiban treatment, noticed without any
complication was observed. Coronary angiograms sup-
port our concept of the use of GP IIb/IIIa receptors block-
ers in this case.
Identification and successful treatment of similar cases
with tirofiban will help in further understanding of the
pathophysiology of acute coronary syndromes in patients
with ET.
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